source
- Argenx shares tumble 15% after Phase 3 Sjögren’s study of Vyvgart halted for futilityArgenx reported that an independent monitoring board recommended stopping its Phase 3 trial of Vyvgart in Sjögren’s disease due to futility, based on an interim analysis. The decision came earlier…
- Argenx halts late-stage Vyvgart trial in Sjogren’s disease after futility finding, shares tumble 13%Argenx announced it is ending the Phase 3 UNITY trial of its Vyvgart Hytrulo injection in Sjogren’s disease after an independent data monitoring committee concluded the study would not meet its pri…